Crispr Therapeutics AG (GB:0VRQ)

Crispr Therapeutics AG (0VRQ) Share Price & Analysis


0VRQ Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$39.30 - $86.33
Previous Close$64.21
Average Volume (3M)2.50K
Market Cap
Enterprise Value$3.49B
Total Cash (Recent Filing)$1.88B
Total Debt (Recent Filing)$240.27M
Price to Earnings (P/E)-9.6
Aug 08, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.72
Shares Outstanding78,935,098
10 Day Avg. Volume1,090
30 Day Avg. Volume2,504
Standard Deviation0.25
Financial Highlights & Ratios
Price to Book (P/B)2.73
Price to Sales (P/S)132.42
Price to Cash Flow (P/CF)143.60
P/FCF Ratio143.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue34.79
Enterprise Value/Gross Profit-31.76
Enterprise Value/Ebitda-6.63
Price Target Upside16.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18




What was Crispr Therapeutics AG’s price range in the past 12 months?
Crispr Therapeutics AG lowest share price was $39.30 and its highest was $86.33 in the past 12 months.
    What is Crispr Therapeutics AG’s market cap?
    Currently, no data Available
    When is Crispr Therapeutics AG’s upcoming earnings report date?
    Crispr Therapeutics AG’s upcoming earnings report date is Aug 08, 2023 which is in 64 days.
      How were Crispr Therapeutics AG’s earnings last quarter?
      Crispr Therapeutics AG released its earnings results on May 08, 2023. The company reported -$0.67 earnings per share for the quarter, beating the consensus estimate of -$1.741 by $1.071.
        Is Crispr Therapeutics AG overvalued?
        According to Wall Street analysts Crispr Therapeutics AG’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Crispr Therapeutics AG pay dividends?
          Crispr Therapeutics AG does not currently pay dividends.
          What is Crispr Therapeutics AG’s EPS estimate?
          Crispr Therapeutics AG’s EPS estimate is -$2.13.
            How many shares outstanding does Crispr Therapeutics AG have?
            Crispr Therapeutics AG has 78,935,100 shares outstanding.
              What happened to Crispr Therapeutics AG’s price movement after its last earnings report?
              Crispr Therapeutics AG reported an EPS of -$0.67 in its last earnings report, beating expectations of -$1.741. Following the earnings report the stock price went up 8.976%.
                Which hedge fund is a major shareholder of Crispr Therapeutics AG?
                Among the largest hedge funds holding Crispr Therapeutics AG’s share is ARK Investment Management LLC. It holds Crispr Therapeutics AG’s shares valued at 361M.


                  Crispr Therapeutics AG Stock Smart Score

                  The Crispr Therapeutics AG Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Crispr Therapeutics AG

                  CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Crispr Therapeutics AG
                  MoonLake Immunotherapeutics
                  VectivBio Holding
                  Bluebird Bio
                  Sangamo Biosciences

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis